Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! 

China Clinical Trials 2017

Analysis of IND and NDA applications and approvals in China 2011-2017

Download free report on life science investment in China

ChinaBio® and BioCentury Boost News Flow from China’s Life Science Industry

publication date: Jun 13, 2012
author/source: Richard Daverman, PhD
ChinaBio® LLC and BioCentury Publications, Inc. announced they have agreed to a collaboration that will make news about China’s rapidly growing biopharma industry more readily available to a global audience. BioCentury, the internationally respected source of biopharma business intelligence, will be a gateway to articles from ChinaBio® Today, the most widely read source of China-focused pharmaceutical news.

Beginning today, BioCentury will feature ChinaBio® Today’s “Week in Review” summary of each week’s major stories at www.biocentury.com. Other major stories from ChinaBio also will be made available on BioCentury’s website in their complete form.

According to ChinaBio's Shanghai research team, China is now the third-largest pharmaceutical market in the world, growing at over 20% per year. Chinese life science companies generated over $5 billion in proceeds from IPOs in 2011, and raised nearly $1 billion in venture capital and private equity funding. There were also over 60 partnering deals, many between Western and Chinese companies, with several reaching total potential deal values of over $100 million.

“China is now an integral part of any life science company’s strategy, and ChinaBio® Today together with BioCentury will detail the development of this rapidly growing market, ” said Greg Scott, CEO and Founder of ChinaBio®. “BioCentury is globally respected for its analysis of the life sciences, and we are honored to have them share our content on China’s dynamic pharma industry.”

“BioCentury respects ChinaBio's efforts to provide access to China's burgeoning biopharma space via its research, conferences and publications such as ChinaBio® Today,” said David Flores, President & CEO of BioCentury. “We expect our readers to find ChinaBio’s coverage of news and events to be indispensable for understanding business opportunities in China.”

ChinaBio® Today is available at www.chinabiotoday.com and BioCentury at www.biocentury.com.


Share this with colleagues:


ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China